Elutia (ELUT) Income from Continuing Operations (2019 - 2026)
Elutia (ELUT) reported Income from Continuing Operations of 7894000.0 for Q1 2026, down 318.34% on a YoY basis from 3615528.64 in Q1 2025, and down 149.26% sequentially from 3167000.0 in Q4 2025.
Elutia (ELUT) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Elutia (ELUT) has 8 years of Income from Continuing Operations data on file, last reported at 7894000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 318.34% year-over-year to 7894000.0; the trailing twelve-month figure through Mar 2026 stood at 21054000.0 (up 38.19% YoY), and the FY2025 full-year result was 12528000.0, up 72.37% from the prior year.
- Income from Continuing Operations fell to 7894000.0 in Q1 2026, from 3167000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3339000.0 in Q3 2024 to a low of 28360000.0 in Q2 2024.
- A 5-year average of 8762000.0 and a median of 8149000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 139.19% in 2024 and tumbled 318.34% in 2026, its largest moves.
- Tracing ELUT's Income from Continuing Operations over 5 years: stood at 6015000.0 in 2022, then tumbled by 153.07% to 15222000.0 in 2023, then jumped by 53.0% to 7155000.0 in 2024, then jumped by 55.74% to 3167000.0 in 2025, then tumbled by 149.26% to 7894000.0 in 2026.
- Business Quant data shows ELUT's Income from Continuing Operations at 7894000.0 in Q1 2026, 3167000.0 in Q4 2025, and 383000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Elutia | 39.99 Mn | 11.50 Mn | 1.80 Mn | -7.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.89 Mn |
| Dec 31, 2025 | -3.17 Mn |
| Sep 30, 2025 | -383,000.00 |
| Jun 30, 2025 | -9.61 Mn |
| Mar 31, 2025 | -1.89 Mn |
| Dec 31, 2024 | -7.16 Mn |
| Sep 30, 2024 | 3.34 Mn |
| Jun 30, 2024 | -28.36 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | -15.22 Mn |
| Sep 30, 2023 | -8.52 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -9.78 Mn |
| Dec 31, 2022 | -6.02 Mn |
| Sep 30, 2022 | -11.03 Mn |
| Jun 30, 2022 | -9.40 Mn |
| Mar 31, 2022 | -8.15 Mn |
| Dec 31, 2021 | -9.06 Mn |
| Sep 30, 2021 | -8.32 Mn |
| Jun 30, 2021 | -2.39 Mn |